{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:51:02Z","timestamp":1790211062206,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The leukotriene D4 receptors have been detected in human bladder detrusor myocytes, and they can play the role of interstitial cystitis etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>Our study aims to explain the role of mast cells histologically and immunohistochemically in the pathogenesis and the effectiveness of montelukast that leukotriene D4 receptor antagonist in the treatment of interstitial cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      Twenty-four Wistar albino adult female rats were used. Group 1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 8): control (sham) group, Group 2 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 8): interstitial cystitis group, and Group 3 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 8): treatment group. Groups 2 and 3 rats were administered 75 mg\/kg cyclophosphamide four times every three days intraperitoneally. The rats in the treatment group were started on montelukast sodium as 10 mg\/kg, 1 \u00d7 1\/day per orally after the last administration of cyclophosphamide and were given for 14 days. Mast cells in the bladder tissues were examined histologically, and the presence of IL-6, 8, VEGF, and TNF alpha was examined immunohistochemically.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thin transitional epithelium, loose connective tissue, weak smooth muscle bundles, and signs of chronic inflammation were observed in the interstitial cystitis group. Regenerated transitional epithelium, intact basement membrane, compact lamina propia, thick smooth muscle bundles, and rare inflammatory cells were observed after the treatment with the montelukast. Mast cells were decreased in bladder tissue after treatment. IL-6, IL-8, VEGF, and TNF alpha levels were significantly decreased after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We found that inflammatory mediators were significantly reduced after treatment with montelukast in the interstitial cystitis group. Montelukast can be used as an effective drug in the treatment of interstitial cystitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_385_22","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:51:01Z","timestamp":1683877861000},"page":"397-403","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Can Montelukast Sodium be an Alternative Treatment in the Treatment of Interstitial Cystitis?"],"prefix":"10.4103","volume":"26","author":[{"given":"\u00d6C","family":"G\u00fcnizi","sequence":"first","affiliation":[{"name":"Department of Medical Pathology, Alanya Alaaddin Keykubat University, Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kol","sequence":"additional","affiliation":[{"name":"Department of Urology, Aydin Adnan Menderes University, Faculty of Medicine, Aydin, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"G\u00fcnizi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Alanya Alaaddin Keykubat University, Faculty of Medicine, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"R1-20240907","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0038-1676089","article-title":"Interstitial cystitis\/bladder pain syndrome","volume":"36","author":"Marcu","year":"2018","journal-title":"Semin Reprod Med"},{"key":"R2-20240907","first-page":"379","article-title":"Advances in therapy with antileukotriene drugs","volume":"34","author":"Riccioni","year":"2004","journal-title":"Ann Clin Lab Sci"},{"key":"R3-20240907","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","article-title":"Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis:An ESSIC proposal","volume":"53","author":"Van de Merwe","year":"2008","journal-title":"Eur Urol"},{"key":"R4-20240907","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756287211398255","article-title":"Role of inflammation in bladder function and interstitial cystitis","volume":"3","author":"Grover","year":"2011","journal-title":"Ther Adv Urol"},{"key":"R5-20240907","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/nau.23365","article-title":"Digital quantitative analysis of mast cell infiltration in interstitial cystitis","volume":"37","author":"Akiyama","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"R7-20240907","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410x.2001.02135.x","article-title":"The action of cysteinyl-leukotrienes on intracellular calcium mobilization in human detrusor myocytes","volume":"87","author":"Bouchelouche","year":"2001","journal-title":"BJU Int"},{"key":"R8-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2003.10.041","article-title":"Critical role of mast cells in inflammatory diseases and the effect of acute stress","volume":"146","author":"Theoharides","year":"2004","journal-title":"J Neuroimmunol"},{"key":"R9-20240907","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0022-5347(05)65663-7","article-title":"The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis","volume":"166","author":"Bouchelouche","year":"2001","journal-title":"J Urol"},{"key":"R10-20240907","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-5347(17)43863-8","article-title":"Chronic interstitial cystitis:A heterogeneous syndrome","volume":"137","author":"Fall","year":"1987","journal-title":"J Urol"},{"key":"R11-20240907","first-page":"9","article-title":"Etiology, pathogenesis, and diagnosis of \u0131nterstitial cystitis","volume":"4","author":"Sant","year":"2002","journal-title":"Rev Urol"},{"key":"R12-20240907","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/01.ju.0000145591.35569.9e","article-title":"Bladder A afferent nerve activity in normal cats and cats with feline interstitial cystitis","volume":"173","author":"Roppolo","year":"2005","journal-title":"J Urol"},{"key":"R13-20240907","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.21.120601.141025","article-title":"Mast cells as \u201ctunable\u201deffector and immunoregulatory cells:Recent advances","volume":"23","author":"Galli","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"R14-20240907","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00305238","article-title":"Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation","volume":"262","author":"Kops","year":"1990","journal-title":"Cell Tissue Res"},{"key":"R15-20240907","article-title":"Houttuynia cordata extract ameliorates bladder damage and improves bladder symptoms via anti-inflammatory effect in rats with interstitial cystitis","author":"Li","year":"2020","journal-title":"ECAM"},{"key":"R16-20240907","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0022-5347(05)67873-1","article-title":"Recruitment, distribution and phenotypes of mast cells in interstitial cystitis","volume":"163","author":"Peeker","year":"2000","journal-title":"J Urol"},{"key":"R17-20240907","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.juro.2008.01.047","article-title":"Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis\/painful bladder syndrome","volume":"179","author":"Erickson","year":"2008","journal-title":"J Urol"},{"key":"R18-20240907","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejogrb.2013.12.041","article-title":"Interstitial cystitis\/painful bladder syndrome:Epidemiology, pathophysiology and evidence-based treatment options","volume":"175","author":"Davis","year":"2014","journal-title":"Eur J Obstet Gynecol"},{"key":"R19-20240907","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00068-003-1284-6","article-title":"In vivo effect of tumor necrosis factor alpha on wound angiogenesis and epithelialization","volume":"29","author":"Frank","year":"2003","journal-title":"Eur J Trauma"},{"key":"R20-20240907","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tcmj.2015.09.006","article-title":"Pathophysiology of interstitial cystitis\/bladder pain syndrome","volume":"27","author":"Ke","year":"2015","journal-title":"Tzu Chi Med"},{"key":"R21-20240907","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0022-5347(05)64750-7","article-title":"Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha","volume":"168","author":"Batler","year":"2002","journal-title":"J Urol"},{"key":"R22-20240907","doi-asserted-by":"crossref","first-page":"F741","DOI":"10.1152\/ajprenal.00081.2006","article-title":"Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis","volume":"291","author":"Chen","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"R23-20240907","doi-asserted-by":"crossref","first-page":"G5","DOI":"10.1152\/ajpgi.00107.2007","article-title":"Pathogenic angiogenesis in IBD and experimental colitis:New ideas and therapeutic avenues","volume":"293","author":"Chidlow","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R24-20240907","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1464-410X.2009.08467.x","article-title":"Increased vascular endothelial growth factor expression in patients with bladder pain syndrome\/interstitial cystitis:\u0130ts association with pain severity and glomerulations","volume":"104","author":"Kiuchi","year":"2009","journal-title":"BJU Int"},{"key":"R25-20240907","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1464-410X.2009.08847.x","article-title":"Bladder pain syndrome\/interstitial cystitis in a Danish population:A study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis","volume":"105","author":"Richter","year":"2010","journal-title":"BJU Int"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_385_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:08:10Z","timestamp":1787760490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_385_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_385_22","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}